Balyasny Asset Management LLC Terns Pharmaceuticals, Inc. Transaction History

Balyasny Asset Management LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$4.54 - $8.2 $86,990 - $157,120	19,161 New	19,161 $130,000
Q4 2023 Feb 14, 2024	BUY	$3.37 - $6.86 $46,687 - $95,038	13,854 New	13,854 $89,000
Q2 2023 Aug 14, 2023	BUY	$7.35 - $13.29 $1.59 Million - $2.87 Million	215,980 Added 58.74%	583,651 $5.11 Million
Q1 2023 May 15, 2023	BUY	$7.91 - $12.0 $2.91 Million - $4.41 Million	367,671 New	367,671 $4.35 Million
Q3 2021 Nov 15, 2021	SELL	$7.22 - $13.46 $74,423 - $138,745	-10,308 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$12.26 - $22.0 $126,376 - $226,776	10,308 New	10,308 $126,000

167

78.3M

580K

454K

Ticker TERN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,613,800
Market Cap $214M
Description
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical t...

Get notified when there are updates to the investment portfolio of Balyasny Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Balyasny Asset Management LLC with notifications on news.